PDF(Pubmed)
Abstract：
UNASSIGNED: Metastasis and drug resistance are the main causes of renal cell carcinoma (RCC) mortality. Currently, there are still a limited number of targeted therapies against advanced RCC. It is critical to develop new effective clinical biomarkers and drug targets in RCC. Several studies have shown that centromere protein F (CENPF), a microtubule binding protein, promotes cancer progression in various types of cancer. The purpose of this study was to explore the role of CENPF in RCC.
UNASSIGNED: Peripheral blood and corresponding tissue samples of 23 RCC patients and 23 normal physical examination patients who were treated in our hospital from 2018 to 2020 were collected, and CENPF expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemical (IHC) methods. The expression of CENPF was downregulated by small interfering RNA (siRNA) transfection, and the proliferation of the corresponding RCC cells and the corresponding cell cycle were detected.
UNASSIGNED: According to The Cancer Genome Atlas (TCGA) data analysis, CENPF is highly expressed in RCC, and its expression level is significantly related to the overall survival (OS) and recurrence-free survival (RFS) of RCC. In addition, high expression of CENPF was found in the tissues of RCC patients in our hospital. Knockdown of CENPF significantly reduced the proliferation of RCC cells in vitro, and knockdown of CENPF regulated the cell cycle by inhibiting the expression of cyclins such as CDK4, CDK6, and CyclinD1.
UNASSIGNED: CENPF can be used as an independent prognostic factor of RCC and regulate the proliferation ability and cell cycle of RCC cells. CENPF is a potential oncogene and prognostic marker in RCC.
UNASSIGNED: Peripheral blood and corresponding tissue samples of 23 RCC patients and 23 normal physical examination patients who were treated in our hospital from 2018 to 2020 were collected, and CENPF expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemical (IHC) methods. The expression of CENPF was downregulated by small interfering RNA (siRNA) transfection, and the proliferation of the corresponding RCC cells and the corresponding cell cycle were detected.
UNASSIGNED: According to The Cancer Genome Atlas (TCGA) data analysis, CENPF is highly expressed in RCC, and its expression level is significantly related to the overall survival (OS) and recurrence-free survival (RFS) of RCC. In addition, high expression of CENPF was found in the tissues of RCC patients in our hospital. Knockdown of CENPF significantly reduced the proliferation of RCC cells in vitro, and knockdown of CENPF regulated the cell cycle by inhibiting the expression of cyclins such as CDK4, CDK6, and CyclinD1.
UNASSIGNED: CENPF can be used as an independent prognostic factor of RCC and regulate the proliferation ability and cell cycle of RCC cells. CENPF is a potential oncogene and prognostic marker in RCC.
摘要：
UNASSIGNED：转移和耐药性是肾细胞癌（RCC）死亡的主要原因。目前,针对晚期RCC的靶向治疗仍然有限.在肾癌中开发新的有效的临床生物标志物和药物靶标至关重要。一些研究表明着丝粒蛋白F(CENPF)，一种微管结合蛋白，促进各种类型癌症的癌症进展。本研究旨在探讨CENPF在RCC中的作用。
UNASSIGNED：收集2018-2020年我院收治的23例RCC患者和23例正常体检患者的外周血及相应组织标本。通过定量实时聚合酶链反应（qRT-PCR）检测CENPF的表达，westernblot,免疫组织化学(IHC)方法。小干扰RNA(siRNA)转染下调CENPF的表达,并检测相应RCC细胞的增殖和相应的细胞周期。
未经证实：根据癌症基因组图谱（TCGA）数据分析，CENPF在RCC中高表达，其表达水平与RCC的总生存期(OS)和无复发生存期(RFS)显著相关。此外,在我院RCC患者组织中发现CENPF高表达。敲除CENPF可显著降低体外RCC细胞的增殖,CENPF的敲除通过抑制细胞周期蛋白如CDK4、CDK6和CyclinD1的表达来调节细胞周期。
UNASSIGNED：CENPF可作为RCC的独立预后因子，调节RCC细胞的增殖能力和细胞周期。CENPF是RCC的潜在癌基因和预后标志物。
UNASSIGNED：收集2018-2020年我院收治的23例RCC患者和23例正常体检患者的外周血及相应组织标本。通过定量实时聚合酶链反应（qRT-PCR）检测CENPF的表达，westernblot,免疫组织化学(IHC)方法。小干扰RNA(siRNA)转染下调CENPF的表达,并检测相应RCC细胞的增殖和相应的细胞周期。
未经证实：根据癌症基因组图谱（TCGA）数据分析，CENPF在RCC中高表达，其表达水平与RCC的总生存期(OS)和无复发生存期(RFS)显著相关。此外,在我院RCC患者组织中发现CENPF高表达。敲除CENPF可显著降低体外RCC细胞的增殖,CENPF的敲除通过抑制细胞周期蛋白如CDK4、CDK6和CyclinD1的表达来调节细胞周期。
UNASSIGNED：CENPF可作为RCC的独立预后因子，调节RCC细胞的增殖能力和细胞周期。CENPF是RCC的潜在癌基因和预后标志物。
